Review Process for New Drug Therapies

The province of Newfoundland and Labrador is an active participant in four initiatives aiming to share provincial and territorial resources related to the assessment of clinical and cost effectiveness of new drug therapies:

- The National Common Drug Review
- The pan-Canadian Oncology Drug Review
- The Atlantic Common Drug Review
- The pan-Canadian Pharmaceutical Alliance

I. The National Common Drug Review (CDR), at Canada's Drug Agency (CDA-AMC), is a pan-Canadian process for conducting objective, rigorous reviews of the clinical, cost-effectiveness, and patient evidence for drugs. CDR also provides formulary listing recommendations to Canada's publicly funded drug plans (except Quebec).

The submission requirement for CDR can be found at: Submit a Drug for CDR Review | CDA-AMC

An electronic copy of this submission, including a province-specific budget impact assessment must also be sent to: NIDPF_NLPDPdrugsubmission@gov.nl.ca

II. The pan-Canadian Oncology Drug Review (pCODR) was established by the provincial and territorial Ministries of Health (excluding Quebec) to assess the clinical evidence and cost effectiveness of new cancer drugs and to use this information to make recommendations to provincial and territorial public drug plans to guide drug funding decisions.

The submission requirements for pCODR can be found at: Submit a Drug for pCODR Review | CDA-AMC

An electronic copy of this submission, including a province-specific budget impact assessment must also be sent to: NIDPF_NLPDPdrugsubmission@gov.nl.ca.

III. The Atlantic Common Drug Review (ACDR) assesses the clinical and cost effectiveness of drugs that do not fall under the mandates of the CDR or the pCODR and provides benefit listing recommendations to the publicly funded drug plans in Atlantic Canada.

The submission requirements for ACDR can be found at:

https://novascotia.ca/dhw/pharmacare/atlantic-common-drug-review.asp

An electronic copy of this submission, including a province-specific budget impact assessment must also be sent to: NIDPF_NLPDPdrugsubmission@gov.nl.ca.

IV. The Pan-Canadian Pharmaceutical Alliance (pCPA) conducts joint provincial/territorial negotiations for brand name and generic drugs in Canada to achieve greater value for publicly funded drug programs and patients. Due to combined “buying power” of drug plans across multiple provinces and territories, the pCPA aims to:

a. Achieve lower drug costs and consistent pricing

b. Increase access to clinically relevant and cost-effective drug treatment options

c. Improve consistency of coverage criteria across Canada

d. Reduce duplication and optimize resource utilization